Delgocitinib
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 151 publications
Efficacy and Safety of Topical 1.5% Ruxolitinib for Chronic Hand Eczema in Real‑World Practice.
Journal: Journal of cutaneous medicine and surgery
Published: June 23, 2026
Letter: Real-Life Improvement in Quality of Life With Delgocitinib in Chronic Hand Eczema.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: June 19, 2026
Emerging topical nonsteroidal therapies in pediatric dermatology: atopic dermatitis, psoriasis, alopecia areata, vitiligo, and seborrheic dermatitis.
Journal: Current opinion in pediatrics
Published: June 04, 2026
Budget impact analysis of delgocitinib for moderate to severe Chronic Hand Eczema in the United States.
Journal: Journal of medical economics
Published: May 27, 2026
Advanced Topical Nonsteroidal Therapies for Atopic Dermatitis: Consensus Statements from an Expert Panel.
Journal: Journal of drugs in dermatology : JDD
Published: March 11, 2026
Successful Treatment of Granulomatous Dermatitis With Topical Delgocitinib.
Journal: JAMA dermatology
Published: March 11, 2026
Expert Consensus on Advanced Topical Nonsteroidal Therapies for Chronic Hand Eczema.
Journal: Journal of drugs in dermatology : JDD
Published: March 04, 2026
Acral Persistent Papular Mucinosis Treated With Topical Delgocitinib.
Journal: The Journal of dermatology
Published: March 03, 2026
Drugs for atopic dermatitis.
Journal: The Medical letter on drugs and therapeutics
Published: February 23, 2026
The Patient Journey: From Diagnosis to Therapeutic Management of Chronic Hand Eczema.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: February 06, 2026
Topical delgocitinib in severe chronic hand eczema: an alternative to systemic therapy with practical considerations and economic impact.
Journal: Clinical and experimental dermatology
Published: February 05, 2026
Delgocitinib cream for adolescents with moderate to severe chronic hand eczema (DELTA TEEN): a multicentre, double-blind, phase 3 randomised controlled trial.
Journal: The Lancet. Child & adolescent health
Published: January 29, 2026
Last Updated: 06/30/2026